Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed announces participation in two virtual investor conferences. The company will present at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 11:40 a.m. ET, and at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET. Webcasts of both events will be available on Insmed's investor relations website and archived for 30 days. Insmed focuses on developing therapies for serious and rare diseases, with its first commercial product approved for a chronic lung disease.
Insmed Incorporated (Nasdaq: INSM) has announced positive topline results from a Phase 1 study of treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. The study demonstrated that TPIP is generally safe and well tolerated, supporting once-daily dosing. The trial involved 42 participants and assessed both single and multiple doses, with the highest single dose being 675 µg. Common mild adverse events included cough and headache. Insmed plans further clinical development of TPIP for pulmonary arterial hypertension (PAH) and other pulmonary disorders, with additional studies expected in 2021.
Insmed Incorporated (Nasdaq: INSM) has announced the release of topline data from its Phase 1 trial of treprostinil palmitil inhalation powder (TPIP) on February 19, 2021. This trial targets the treatment of pulmonary arterial hypertension (PAH) and rare pulmonary disorders. A conference call for investors will be held at 8:30 a.m. ET on the same day to discuss the findings and provide updates. TPIP is a unique formulation developed in-house, showcasing Insmed's commitment to addressing unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) will release its fourth-quarter and full-year 2020 financial results on February 25, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Interested participants can join by dialing the provided numbers or via a live webcast. The replay of the call will be available two hours post completion until March 27, 2021. Insmed focuses on therapies for serious rare diseases, with its first product approved for a chronic lung disease.
On February 5, 2021, Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 14 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards included options for a total of 65,980 shares of common stock at an exercise price of $37.44 per share, aligning with the closing price on February 1, 2021. The options have a ten-year term and a four-year vesting schedule, promoting employee retention and aligning interests with shareholder value.
Insmed, a biopharmaceutical company focused on rare and serious diseases, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 7:30 a.m. ET. This event will be available for live streaming and archived for 30 days. Insmed's mission is to improve patient lives through innovative therapies, including its first commercial product for a lung disease and a pipeline targeting unmet medical needs in inflammatory diseases and rare pulmonary disorders. More information can be found on www.insmed.com.
Insmed announced that the first patient was dosed in December 2020 for the frontline clinical trial program of ARIKAYCE® in treating nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). This program includes ARISE, a study validating patient-reported outcome tools, and ENCORE, a pivotal trial assessing ARIKAYCE's efficacy and safety. ARIKAYCE, the first FDA-approved therapy for MAC lung disease, aims to secure full approval and support supplemental drug applications. The trials seek to establish ARIKAYCE as a new standard of care.
Insmed Incorporated (Nasdaq: INSM) announced on December 4, 2020, the granting of inducement awards to seven new employees as part of NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 13,560 shares at an exercise price of $39.14, reflecting the closing price on December 1, 2020. The options have a ten-year term and a four-year vesting schedule, with 25% vesting after one year and 12.5% every six months thereafter, contingent on continued employment.
Insmed announced the dosing of the first patient in the Phase 3 ASPEN study evaluating brensocatib for bronchiectasis treatment. This Phase 3 trial is centered on exploring the efficacy and safety of brensocatib, which has shown promising results in the Phase 2 WILLOW study. Approximately 1,620 patients across 40 countries will participate, with a primary focus on pulmonary exacerbation rates over 52 weeks. Brensocatib has received Breakthrough Therapy and PRIME designations, indicating its potential importance in addressing this serious condition.
Insmed Incorporated (Nasdaq: INSM) announced its participation in the virtual Evercore ISI 3rd Annual HealthCONx Conference, scheduled for December 1, 2020, at 8:00 a.m. ET. This presentation aims to showcase the company's advancements in treating serious and rare diseases. The event will include a live webcast accessible through their investor relations page, with an archived version available for 30 days post-event. Insmed's mission focuses on transforming the lives of patients with chronic pulmonary diseases and other unmet medical needs.